Weight Watchers Pivots to Clinical Model Amid GLP-1 Boom
Event summary
- Weight Watchers reported Q4 2025 revenue of $163M, down 12% YoY, but clinical subscription revenue grew 32% YoY to $27M.
- Total subscribers declined to 2.8M, but clinical subscribers surged 42% YoY to 130K.
- Company expects 2026 revenue between $620M-$635M and Adjusted EBITDA of $105M-$115M.
- Weight Watchers is shifting focus to integrating GLP-1 medications with behavioral support.
The big picture
Weight Watchers is navigating a profound industry transformation driven by GLP-1 medications. The company is evolving its business model to combine medication access with its long-standing behavioral support and community offerings. This strategic shift aims to position Weight Watchers as a leader in the weight health market, despite facing secular pressures in its traditional behavioral business.
What we're watching
- Clinical Growth
- Whether Weight Watchers can sustain its 42% YoY growth in clinical subscribers amid increasing competition in the GLP-1 market.
- Revenue Mix Shift
- How the accelerating shift from behavioral to clinical subscriptions will impact Weight Watchers' average revenue per user (ARPU).
- Market Positioning
- The pace at which Weight Watchers can establish itself as the premier global destination for weight health in the GLP-1 era.
Related topics